The GLP-1 receptor agonist market size has grown steadily in recent years. It will grow from $13.58 billion in 2024 to $14.22 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to rising diabetes prevalence, clinical efficacy, patient awareness and acceptance, global health initiatives, patient preference for injectable therapies.
The GLP-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to $17.72 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to increasing emphasis on lifestyle management, growing personalized medicine approaches, expanding indications, development of next-generation products, integration into combination therapies. Major trends in the forecast period include introduction of oral formulations, focus on combination therapies, strategic partnerships and collaborations, reimbursement policies and access, patient-centric approaches.
The increasing prevalence of diabetes is anticipated to drive the growth of the GLP-1 receptor agonist market in the future. Diabetes is a chronic condition that occurs when the pancreas either produces insufficient insulin or when the body is unable to effectively utilize the insulin it produces. High blood sugar levels are a key symptom of the metabolic disorder known as diabetes mellitus. GLP-1 receptor agonists are utilized in diabetes treatment to stimulate the body to produce more insulin, thereby helping to lower blood sugar levels. As a result, the rising prevalence of diabetes will boost market growth. For example, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, indicated that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, it rose by 21%. Additionally, the percentage of individuals achieving target HbA1c levels climbed to 37.9%, marking the highest figure ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of diabetes is fueling the growth of the GLP-1 receptor agonist market.
The growth of the GLP-1 receptor agonist market is also expected to be boosted by the increasing cases of obesity. Obesity, a medical condition characterized by excessive body fat accumulation, is associated with various health risks. GLP-1 receptor agonists have shown effectiveness in treating obesity by mimicking the effects of the naturally occurring hormone GLP-1, which regulates appetite and blood sugar levels. According to the World Health Organization's March 2022 report, over 1 billion individuals globally are affected by obesity, including 650 million adults, 340 million adolescents, and 39 million children, with this number continuing to rise. It is estimated that around 167 million people may experience compromised health due to being overweight or obese. Therefore, the increasing prevalence of obesity is contributing to the growth of the GLP-1 receptor agonist market.
A key trend gaining momentum in the GLP-1 receptor agonist market is product innovation, with major companies focusing on developing innovative solutions to strengthen their market position. For instance, in May 2022, Eli Lilly and Company launched Mounjaro, an FDA-approved GIP and GLP-1 receptor agonist designed using a single molecule to activate the body's receptors for incretin hormones. This product is available as a pen auto-injector with a pre-attached, hidden needle, providing convenience for patients.
Major companies in the GLP-1 receptor agonist market are concentrating on developing sustained-release GLP-1 receptor agonists to gain a competitive edge. Sustained-release GLP-1 receptor agonists slowly release the medication into the bloodstream, allowing for longer-lasting effects and less frequent injections compared to traditional GLP-1 receptor agonists. Mitsubishi Tanabe Pharma Corporation launched Mounjaro 2.5 mg or 5 mg Ateos in April 2023, which is the world's first sustained-release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes.
In February 2022, Sanofi S.A. strengthened its position in the market by acquiring Amunix Pharmaceuticals Inc., a US-based immuno-oncology company developing GLP-1 receptor agonists and transformative therapies for cancer. The acquisition is expected to provide Sanofi access to various products and technologies, including next-generation conditionally activated biologics.
Major companies operating in the GLP-1 receptor agonist market include Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG.
North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the glp-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glp-1 receptor agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
A GLP-1 receptor agonist is a type of medication designed to stimulate insulin release when blood glucose levels are elevated and to inhibit glucagon secretion in the presence of low blood glucose conditions. These medications are primarily employed in the treatment of type 2 diabetes mellitus.
The main drug class of GLP-1 receptor agonists includes liraglutide, dulaglutide, lixisenatide, and others. Liraglutide, for instance, is a GLP-1 receptor agonist that facilitates the release of an appropriate amount of insulin from the pancreas in response to elevated blood sugar levels. These medications are administered through parenteral and oral routes, commonly utilized in settings such as hospitals, surgical clinics, and other medical facilities.
The GLP-1 receptor agonist market research report is one of a series of new reports that provides GLP-1 receptor agonist market statistics, including GLP-1 receptor agonist industry global market size, regional shares, competitors with GLP-1 receptor agonist market share, detailed GLP-1 receptor agonist market segments, market trends, and opportunities, and any further data you may need to thrive in the GLP-1 receptor agonist industry. This GLP-1 receptor agonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The GLP-1 receptor agonist market consists of sales of dulaglutide, bydureon b-cise, exenatide, and semaglutide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The GLP-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to $17.72 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to increasing emphasis on lifestyle management, growing personalized medicine approaches, expanding indications, development of next-generation products, integration into combination therapies. Major trends in the forecast period include introduction of oral formulations, focus on combination therapies, strategic partnerships and collaborations, reimbursement policies and access, patient-centric approaches.
The increasing prevalence of diabetes is anticipated to drive the growth of the GLP-1 receptor agonist market in the future. Diabetes is a chronic condition that occurs when the pancreas either produces insufficient insulin or when the body is unable to effectively utilize the insulin it produces. High blood sugar levels are a key symptom of the metabolic disorder known as diabetes mellitus. GLP-1 receptor agonists are utilized in diabetes treatment to stimulate the body to produce more insulin, thereby helping to lower blood sugar levels. As a result, the rising prevalence of diabetes will boost market growth. For example, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, indicated that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, it rose by 21%. Additionally, the percentage of individuals achieving target HbA1c levels climbed to 37.9%, marking the highest figure ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of diabetes is fueling the growth of the GLP-1 receptor agonist market.
The growth of the GLP-1 receptor agonist market is also expected to be boosted by the increasing cases of obesity. Obesity, a medical condition characterized by excessive body fat accumulation, is associated with various health risks. GLP-1 receptor agonists have shown effectiveness in treating obesity by mimicking the effects of the naturally occurring hormone GLP-1, which regulates appetite and blood sugar levels. According to the World Health Organization's March 2022 report, over 1 billion individuals globally are affected by obesity, including 650 million adults, 340 million adolescents, and 39 million children, with this number continuing to rise. It is estimated that around 167 million people may experience compromised health due to being overweight or obese. Therefore, the increasing prevalence of obesity is contributing to the growth of the GLP-1 receptor agonist market.
A key trend gaining momentum in the GLP-1 receptor agonist market is product innovation, with major companies focusing on developing innovative solutions to strengthen their market position. For instance, in May 2022, Eli Lilly and Company launched Mounjaro, an FDA-approved GIP and GLP-1 receptor agonist designed using a single molecule to activate the body's receptors for incretin hormones. This product is available as a pen auto-injector with a pre-attached, hidden needle, providing convenience for patients.
Major companies in the GLP-1 receptor agonist market are concentrating on developing sustained-release GLP-1 receptor agonists to gain a competitive edge. Sustained-release GLP-1 receptor agonists slowly release the medication into the bloodstream, allowing for longer-lasting effects and less frequent injections compared to traditional GLP-1 receptor agonists. Mitsubishi Tanabe Pharma Corporation launched Mounjaro 2.5 mg or 5 mg Ateos in April 2023, which is the world's first sustained-release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes.
In February 2022, Sanofi S.A. strengthened its position in the market by acquiring Amunix Pharmaceuticals Inc., a US-based immuno-oncology company developing GLP-1 receptor agonists and transformative therapies for cancer. The acquisition is expected to provide Sanofi access to various products and technologies, including next-generation conditionally activated biologics.
Major companies operating in the GLP-1 receptor agonist market include Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG.
North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the glp-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glp-1 receptor agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
A GLP-1 receptor agonist is a type of medication designed to stimulate insulin release when blood glucose levels are elevated and to inhibit glucagon secretion in the presence of low blood glucose conditions. These medications are primarily employed in the treatment of type 2 diabetes mellitus.
The main drug class of GLP-1 receptor agonists includes liraglutide, dulaglutide, lixisenatide, and others. Liraglutide, for instance, is a GLP-1 receptor agonist that facilitates the release of an appropriate amount of insulin from the pancreas in response to elevated blood sugar levels. These medications are administered through parenteral and oral routes, commonly utilized in settings such as hospitals, surgical clinics, and other medical facilities.
The GLP-1 receptor agonist market research report is one of a series of new reports that provides GLP-1 receptor agonist market statistics, including GLP-1 receptor agonist industry global market size, regional shares, competitors with GLP-1 receptor agonist market share, detailed GLP-1 receptor agonist market segments, market trends, and opportunities, and any further data you may need to thrive in the GLP-1 receptor agonist industry. This GLP-1 receptor agonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The GLP-1 receptor agonist market consists of sales of dulaglutide, bydureon b-cise, exenatide, and semaglutide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. GLP-1 Receptor Agonist Market Characteristics3. GLP-1 Receptor Agonist Market Trends and Strategies4. GLP-1 Receptor Agonist Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global GLP-1 Receptor Agonist Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the GLP-1 Receptor Agonist Market34. Recent Developments in the GLP-1 Receptor Agonist Market
5. Global GLP-1 Receptor Agonist Growth Analysis and Strategic Analysis Framework
6. GLP-1 Receptor Agonist Market Segmentation
7. GLP-1 Receptor Agonist Market Regional and Country Analysis
8. Asia-Pacific GLP-1 Receptor Agonist Market
9. China GLP-1 Receptor Agonist Market
10. India GLP-1 Receptor Agonist Market
11. Japan GLP-1 Receptor Agonist Market
12. Australia GLP-1 Receptor Agonist Market
13. Indonesia GLP-1 Receptor Agonist Market
14. South Korea GLP-1 Receptor Agonist Market
15. Western Europe GLP-1 Receptor Agonist Market
16. UK GLP-1 Receptor Agonist Market
17. Germany GLP-1 Receptor Agonist Market
18. France GLP-1 Receptor Agonist Market
19. Italy GLP-1 Receptor Agonist Market
20. Spain GLP-1 Receptor Agonist Market
21. Eastern Europe GLP-1 Receptor Agonist Market
22. Russia GLP-1 Receptor Agonist Market
23. North America GLP-1 Receptor Agonist Market
24. USA GLP-1 Receptor Agonist Market
25. Canada GLP-1 Receptor Agonist Market
26. South America GLP-1 Receptor Agonist Market
27. Brazil GLP-1 Receptor Agonist Market
28. Middle East GLP-1 Receptor Agonist Market
29. Africa GLP-1 Receptor Agonist Market
30. GLP-1 Receptor Agonist Market Competitive Landscape and Company Profiles
31. GLP-1 Receptor Agonist Market Other Major and Innovative Companies
35. GLP-1 Receptor Agonist Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
GLP-1 Receptor Agonist Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on glp-1 receptor agonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for glp-1 receptor agonist ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glp-1 receptor agonist market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- the market characteristics section of the report defines and explains the market.
- the market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- the forecasts are made after considering the major factors currently impacting the market. These include:
- the forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- the regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- the competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- the trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Drug Class: Exenatide; Liraglutide; Dulaglutide; Lixisenatide; Other Drugs2) by Route of Administration: Parenteral; Oral
3) by End Users: Hospitals; Surgical Clinics; Other Users
Subsegments:
1) by Exenatide: Byetta; Bydureon2) by Liraglutide: Victoza; Saxenda
3) by Dulaglutide: Trulicity
4) by Lixisenatide: Adlyxin
5) by Other Drugs: Semaglutide; Tirzepatide; Others
Key Companies Mentioned: Novo Nordisk a/S; Sanofi SA; Eli Lilly and Company; AstraZeneca Inc.; Boehringer Ingelheim International GmbH
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this GLP-1 Receptor Agonist market report include:- Novo Nordisk A/S
- Sanofi SA
- Eli Lilly and Company
- AstraZeneca Inc.
- Boehringer Ingelheim International GmbH
- Hanmi Pharm Co. Ltd.
- Pfizer Inc.
- Amgen Inc.
- Innovent Biologics Inc.
- Jiangsu Hengrui Medicine Co.
- Sun Pharmaceuticals Industries Ltd.
- PegBio Co. Ltd.
- Zealand Pharma A/S
- Bristol-Myers Squibb Company
- Chongqing Lummy Pharmaceutical Co. Ltd.
- Daiichi Sankyo Company Limited
- Dong-A ST Co. Ltd.
- Eisai Co. Ltd.
- HanAll Biopharma Co. Ltd.
- Ipsen SA
- Johnson & Johnson
- Merck & Co. Inc.
- Novartis AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 14.22 Billion |
| Forecasted Market Value ( USD | $ 17.72 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
